Abbreviated Reports May Be Submitted for Studies Not Central To Efficacy
This article was originally published in The Tan Sheet
Executive Summary
Abbreviated data reports may be submitted for efficacy, safety and pharmacology studies that are not central to efficacy claims for a specific indication, FDA indicates in its guidance for industry on "Submission of Abbreviated Reports and Synopses in Support of Marketing Applications."